CD47 and cancer: In order to improve the effect of anti-CD47 immunotherapy, Rao et al. designed a hybrid cell membrane nanovesicles (known as hNVs), which consists of platelet-derived NVs (P-NVs), M1 macrophage-derived NVs (M1-NVs) and cancer cell-derived NV overexpressing high-affinity SIRP-α variants (SαV-C-NVs).